- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BENEVOLENTAI Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 3,465 | 0,00 % | Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here's What You Should Know | ||
| ABCELLERA BIOLOGICS | 10,600 | +0,95 % | AbCellera-Aktie mit +450% - nächstes Ziel 20 US$? | Die AbCellera-Aktie hat innerhalb weniger Monate eine beeindruckende Rallye hingelegt. Vom Frühjahrstief bei rund 3,00 US$ stieg der Kurs zeitweise bis auf 15,00 US$. Nach diesem Anstieg läuft nun eine... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 1,151 | -0,95 % | Anavex Life Sciences gains IND clearance for blarcamesine in Fragile X syndrome | ||
| VERACYTE | 38,660 | +0,78 % | Veracyte: Medicare übernimmt Kosten für Brustkrebstest Prosigna | ||
| ASCLETIS PHARMA | 0,650 | 0,00 % | ASCLETIS-B (01672): NEXT DAY DISCLOSURE RETURN | ||
| ABSCI | 8,250 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| BIOMEA FUSION | 0,869 | 0,00 % | Biomea posts phase 1 data to pitch oral GLP-1 to potential partners, but investors appear unconvinced | ||
| JASPER THERAPEUTICS | 0,480 | +0,02 % | Jasper Therapeutics, Inc. - 8-K, Current Report | ||
| LANTERN PHARMA | 0,635 | -4,98 % | Lantern Pharma Inc.: Lantern Pharma Secures USPTO Notice of Allowance for LP-284 Treatment Patent in Aggressive B-Cell Lymphomas | Newly allowed claims provide LP-284 patent protection into 2042 for the treatment of mantle cell lymphoma and double-hit lymphoma, two blood cancers with high-unmet-needs
The U.S. Patent and... ► Artikel lesen | |
| QIAGEN | 41,030 | -0,24 % | QIAGEN N.V.: QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis | Global TB Summit brings together international experts as persistent disease burden and funding pressures challenge progress against tuberculosis QuantiFERON-TB Gold Plus detects tuberculosis... ► Artikel lesen | |
| IMMUNOVANT | 26,730 | 0,00 % | Immunovant Q1 2027 Earnings Call: Complete Transcript | ||
| PRAXIS PRECISION MEDICINES | 241,79 | +0,01 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 37,320 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year | Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
Enliven continues preparation for late-stage... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 37,950 | 0,00 % | HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? | ||
| ERASCA | 13,375 | -0,11 % | Erasca drops after sacking COO |
Das Unternehmen BENEVOLENTAI kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BENEVOLENTAI finden Sie auf Wallstreet Online.